Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK to evaluate congenital hip screening:

This article was originally published in Clinica

Executive Summary

A UK government committee is to evaluate the cost-effectiveness of current and alternative strategies for the neonatal screening programme for congenital dislocation of the hip. This follows a report from the Medical Research Council which has questioned the effectiveness of current screening policy which is based on physical examination. The national screening committee will discuss the use of ultrasound which, under present guidelines, is not employed for routine screening in the UK. The evaluatory study will take place over a six-month period, with policy change proposals expected by the end of 1999.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT082752

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel